ATE370960T1 - Verknüpfte peptid-nukleinsäuren - Google Patents

Verknüpfte peptid-nukleinsäuren

Info

Publication number
ATE370960T1
ATE370960T1 AT95928084T AT95928084T ATE370960T1 AT E370960 T1 ATE370960 T1 AT E370960T1 AT 95928084 T AT95928084 T AT 95928084T AT 95928084 T AT95928084 T AT 95928084T AT E370960 T1 ATE370960 T1 AT E370960T1
Authority
AT
Austria
Prior art keywords
peptide nucleic
nucleic acids
strands
peptide
pyrimidines
Prior art date
Application number
AT95928084T
Other languages
English (en)
Inventor
Michael Egholm
Peter Nielsen
Ole Buchardt
Kim Dueholm
Leif Christensen
James Coull
John Kiely
Michael Griffith
Original Assignee
Isis Pharmaceuticals Inc
Perseptive Biosystems Inc
Buchardt Dorte
Michael Egholm
Nielsen Peter Eigil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc, Perseptive Biosystems Inc, Buchardt Dorte, Michael Egholm, Nielsen Peter Eigil filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE370960T1 publication Critical patent/ATE370960T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95928084T 1994-07-15 1995-07-13 Verknüpfte peptid-nukleinsäuren ATE370960T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/275,951 US6451968B1 (en) 1991-05-24 1994-07-15 Peptide nucleic acids

Publications (1)

Publication Number Publication Date
ATE370960T1 true ATE370960T1 (de) 2007-09-15

Family

ID=23054499

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95928084T ATE370960T1 (de) 1994-07-15 1995-07-13 Verknüpfte peptid-nukleinsäuren

Country Status (7)

Country Link
US (1) US6451968B1 (de)
EP (1) EP0773950B1 (de)
JP (1) JP3326181B2 (de)
AT (1) ATE370960T1 (de)
AU (1) AU3196795A (de)
DE (1) DE69535575D1 (de)
WO (1) WO1996002558A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105286A1 (en) * 1991-05-24 2003-06-05 Michael Egholm Linked peptide nucleic acids
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
ES2288760T3 (es) 1996-04-25 2008-01-16 Bioarray Solutions Ltd. Ensamblaje electrocinetico controlado por luz de particulas proximas a superficies.
US6617422B1 (en) 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
US6300318B1 (en) * 1997-09-16 2001-10-09 Peter E. Nielsen Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
EP1025120B1 (de) 1997-10-27 2010-08-18 Boston Probes, Inc. Sich auf "pna molecular beacons" beziehende verfahren, testsätze und zusammensetzungen
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US20040063618A1 (en) * 2002-09-30 2004-04-01 Muthiah Manoharan Peptide nucleic acids having improved uptake and tissue distribution
EP1073766A1 (de) 1998-04-29 2001-02-07 Trustees Of Boston University Methoden und zusammensetzungen betreffend pd-loops
GB9815933D0 (en) * 1998-07-23 1998-09-23 Secr Defence Detection method
US6548651B1 (en) 1998-11-11 2003-04-15 Pantheco A/S Modified peptide nucleic acid (PNA) molecules
AU7773000A (en) * 1998-11-11 2001-04-23 Pantheco A/S Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or amorpholino
US9709559B2 (en) 2000-06-21 2017-07-18 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
AU784561B2 (en) * 2000-06-23 2006-05-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Positively-charged peptide nucleic acid analogs with improved properties
DE60216468T2 (de) 2001-03-09 2007-09-27 Boston Probes, Inc., Bedford Kombinationsoligomere betreffende verfahren, kits und zusammensetzungen
US7262063B2 (en) 2001-06-21 2007-08-28 Bio Array Solutions, Ltd. Directed assembly of functional heterostructures
KR20040068122A (ko) 2001-10-15 2004-07-30 바이오어레이 솔루션스 리미티드 공동 검색과 효소-매개된 탐지에 의한 다형성 좌위의 다중분석
US7041453B2 (en) 2002-08-22 2006-05-09 Bioarray Solutions Ltd. Molecular constructs and methods of use for detection of biochemical reactions
AU2003298655A1 (en) 2002-11-15 2004-06-15 Bioarray Solutions, Ltd. Analysis, secure access to, and transmission of array images
GB2422196B (en) * 2003-05-20 2008-05-07 Investigen Inc System for detecting polynucleotides
US7595279B2 (en) 2003-09-22 2009-09-29 Bioarray Solutions Ltd. Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules
DE10346721A1 (de) * 2003-10-08 2005-05-04 Holger Kalthoff Oligonukleotide, diese enthaltende Mittel und deren Verwendung
EP1692298A4 (de) 2003-10-28 2008-08-13 Bioarray Solutions Ltd Optimierung der genexpressionsanalyse unter verwendung immobilisierter fängersonden
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
US7543412B2 (en) * 2004-06-14 2009-06-09 Haworth, Ltd. Wall panel edge rail connector arrangement
US7848889B2 (en) 2004-08-02 2010-12-07 Bioarray Solutions, Ltd. Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification
US7306785B2 (en) * 2004-09-23 2007-12-11 General Electric Company Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using
JP5479731B2 (ja) 2005-06-02 2014-04-23 アドヴァンディーエックス，インコーポレイテッド 微生物を解析するためのペプチド核酸プローブ
US20100041738A1 (en) 2005-06-20 2010-02-18 Avaris Ab Hybridization-stabilizing construct
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
WO2007100711A2 (en) * 2006-02-24 2007-09-07 Investigen, Inc. Methods and compositions for detecting polynucleotides
CA2659632A1 (en) 2006-08-01 2008-02-07 Applera Corporation Detection of analytes and nucleic acids
US20080096193A1 (en) * 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
WO2008072933A1 (en) * 2006-12-15 2008-06-19 Panagene Inc. Peptide nucleic acids conjugated with multi -amine linkers and nucleic acid detecting device using the same
WO2008103702A2 (en) 2007-02-23 2008-08-28 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
US8916531B2 (en) 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression
US7964355B2 (en) * 2009-02-17 2011-06-21 Investigen, Inc. Assays based on detection of photobleaching reaction products from dye catalytic complex
NZ598457A (en) * 2009-08-03 2014-06-27 Recombinetics Inc Methods and compositions for targeted gene modification
JP2013508299A (ja) 2009-10-16 2013-03-07 リブ−エックス ファーマシューティカルズ，インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
CN108456211A (zh) * 2009-10-16 2018-08-28 梅琳塔治疗公司 抗微生物化合物和其制备和使用方法
PH12012500734A1 (en) 2009-10-16 2012-11-26 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
US20140170653A1 (en) 2011-04-15 2014-06-19 Life Technologies Corporation Chemical ligation
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
MX2016002975A (es) 2013-09-09 2016-10-21 Melinta Therapeutics Inc Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos.
EP3038623A4 (de) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimikrobielle verbindungen und verfahren zur herstellung und verwendung davon
SG11201605539SA (en) 2014-01-10 2016-08-30 Glaxosmithkline Ip No 2 Ltd Hydroxy formamide derivatives and their use
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP4331618A3 (de) 2014-05-09 2024-06-12 Yale University Hyperverzweigte polyglycerolbeschichtete partikel und verfahren zur herstellung und verwendung davon
EP3183367B1 (de) 2014-08-19 2019-06-26 Pacific Biosciences Of California, Inc. Zusammensetzungen und verfahren zur anreicherung von nukleinsäuren
BR112017019349A2 (pt) 2015-03-11 2018-06-05 Melinta Therapeutics Inc compostos antimicrobianos e métodos de fabricação e uso dos mesmos
MX391259B (es) 2015-10-14 2025-03-21 X Therma Inc Composiciones y métodos para reducir la formación de cristales de hielo.
EP3416976A2 (de) 2016-02-16 2018-12-26 Yale University Zusammensetzungen zur verbesserung von gezielter geneditierung und verfahren zur verwendung davon
US11098047B2 (en) 2016-05-06 2021-08-24 BioVersys AG Antimicrobials and methods of making and using same
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5235033A (en) * 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
AU5661386A (en) 1985-03-15 1986-10-13 Stirchak, E. Stereoregular polynucleotide-binding polymers
CA1339987C (en) 1988-09-01 1998-08-04 Robert Bruce Merrifield Peptide synthesis method and solid support for use in the method
DE3924705A1 (de) 1989-07-26 1991-01-31 Boehringer Mannheim Gmbh Heterobifunktionelle verbindungen
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
AU668886B2 (en) 1991-08-30 1996-05-23 Johns Hopkins University, The Formation of triple helix complexes of double stranded DNA using nucleoside oligomers which comprise purine base analogs
MX9207334A (es) 1991-12-18 1993-08-01 Glaxo Inc Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
WO1993018187A1 (en) 1992-03-13 1993-09-16 California Institute Of Technology Triple helix recognition of dna
WO1994005268A1 (en) 1992-09-04 1994-03-17 Baylor College Of Medicine Novel triplex forming oligonucleotides and methods for their use
US5324483B1 (en) 1992-10-08 1996-09-24 Warner Lambert Co Apparatus for multiple simultaneous synthesis
AU684774B2 (en) 1992-12-08 1998-01-08 Genta Incorporated Formation of triple helix complexes using a novel motif

Also Published As

Publication number Publication date
JP3326181B2 (ja) 2002-09-17
EP0773950A1 (de) 1997-05-21
EP0773950A4 (de) 2000-05-17
EP0773950B1 (de) 2007-08-22
AU3196795A (en) 1996-02-16
US6451968B1 (en) 2002-09-17
DE69535575D1 (de) 2007-10-04
JPH10503759A (ja) 1998-04-07
WO1996002558A1 (en) 1996-02-01

Similar Documents

Publication Publication Date Title
ATE370960T1 (de) Verknüpfte peptid-nukleinsäuren
FI956019L (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA-C-klooni-10:n kanssa, ja niiden käyttö
EP0986372A4 (de) Vesikuläre komplexe und verfahren zu deren herstellung und verwendung
DK0586618T3 (da) Anvendelse af nuklainsyreanaloger i diagnostiske og analytiske fremgangsmåder
DK1029870T3 (da) Hybride immunglobuliner til anvendelse i terapeutiske fremgangsmåder
ATE225369T1 (de) Doppelsträngige peptidenukleinsäuren
FI953743L (fi) Keratolyyttistä ja/tai finnitaudinvastaista aktiivisuutta omaavia kosmeettisia koostumuksia, niiden valmistus ja käyttö
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
ATE391789T1 (de) Verwendung einer vielzahl von rekombinationsstellen mit einzigartiger spezifität beim rekombinatorischen klonen
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
EP0585257A4 (de) Für natürliche killerzellen spezifische dna- und aminosäuresequenz.
ATA163595A (de) Hochmolekulare und niedermolekulare fraktionen des von willebrand-faktors
CA2278028A1 (en) Methods for improving transformation efficiency
ATE387458T1 (de) Fas-antigenbindender ligand
ATE311402T1 (de) Peptidnukleinsäuren mit erhöhter bindungsaffinität, sequenzspezifität und löslichkeit
DE69332203D1 (de) Multimerische mehrzweckwirkstoffe gegen thrombose
FR2611736B1 (fr) Nouveaux complexes chromiferes 1:2, leur preparation et leur utilisation comme colorants
FI952738L (fi) Stabiiliproteiini, fosfolipidikoostumuksia ja menetelmiä
SE9602822D0 (sv) New receptor
FR2692903B1 (fr) Nouveaux complexes metalliferes 1:2 asymetriques, leur preparation et leur utilisation comme colorants anioniques.
EP0237676A3 (de) Rekombinantes Ricin-Toxin
IE860922L (en) Hair waving compositions
FI933506A7 (fi) Bisyklopolyatsamakrosyklokarboksyylihappokomplekseja, niiden konjugaat teja, menetelmä niiden valmistamiseksi ja käyttö varjoaineina
FR2589873B1 (fr) Nouveaux complexes cupriferes, leur preparation et leur utilisation comme colorants

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties